Karyopharm Therapeutics Inc. diskutieren
Karyopharm Therapeutics Inc.
WKN: A1W77U / Symbol: KPTI / Name: Karyopharm / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
0,54 €
-3,84 %
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target raised by analysts at Barclays PLC from $5.00 to $10.00. They now have an "overweight" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $34.00 to $33.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Robert W. Baird from $42.00 to $25.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Robert W. Baird from $25.00 to $21.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $12.00 price target on the stock, down previously from $15.00.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $15.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Royal Bank Of Canada from $30.00 to $19.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) is now covered by Rodman & Renshaw. They set a "buy" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its price target lowered by Robert W. Baird from $21.00 to $15.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its price target lowered by HC Wainwright from $15.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $8.00 price target on the stock, down from $12.00.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $16.00 price target on the stock, up from $8.00.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its price target raised by HC Wainwright from $8.00 to $13.00. They now have a "buy" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Ratings data for KPTI provided by MarketBeat
Neueste Beiträge
UBS_Group_AG in Weight Watchers International diskutieren